| Literature DB >> 32761295 |
Shiraze M Bulsara1,2, Milton L Wainberg3, Kris Rogers4, John McAloon4, Rachel Grove4, Toby R O Newton-John4.
Abstract
Retention is a central component of the Cascade, facilitating monitoring of comorbidity. Country-specific definitions differ and may suit stable and functioning clients, while not appropriately classifying complex clinical presentations characterized by comorbidity. A retrospective file review of 363 people living with HIV attending a Sydney HIV clinic was conducted. Retention was compared with Australian (attendance once/12-months) and World Health Organization (attendance 'appropriate to need') recommendations to identify those attending according to the Australian definition, but not clinician recommendations (AUnotWHO). Multivariable logistic regression analyses determined the impact of age/sex and clinician-assessed comorbidity on retention. Most (97%) participants were considered retained according to the Australian definition, but only 56.7% according to clinician recommendations. Those with psychosocial comorbidity alone were less likely to be in the AUnotWHO group (OR 0.51, 95%CI 0.27-0.96, p = 0.04). The interaction of physical and psychosocial comorbidity was predictive of poor retention (Wald test: χ2 = 6.39, OR 2.39 [95% CI 1.15-4.97], p = 0.01), suggesting a syndemic relationship.Entities:
Mesh:
Year: 2021 PMID: 32761295 PMCID: PMC7406219 DOI: 10.1007/s10461-020-02992-1
Source DB: PubMed Journal: AIDS Behav ISSN: 1090-7165
Fig. 1Summary of ‘occasions of service’ with inclusion and exclusion criteria
Summary of variables and associated complexity domains in the CCRS-HIV
| Complexity domain | Variable |
|---|---|
| Psychosocial (PSY) | Financial instability Social isolation Problematic Crystal Methamphetamine (CMA) use Mental illness &/or other problematic substance use |
| Physical health (PH) | Cognitive/neurological impairment Polypharmacy Hepatitis C (HCV) &/or Cancer Other physical health comorbidity |
Summary of retention in care (outcome) and covariate variables and descriptive statistics
| Variable category | Category | Variables | Whole sample | AUnotWHO group | ||
|---|---|---|---|---|---|---|
| Mean (SD)/Median (p25–p75) | Number of participants (%) | Mean (SD)/median (p25–p75) | Number of participants (%) | |||
| Outcome | Retained (AU guidelines) | No | – | 11 (3.0) | – | 0 149 (100) |
| Yes | – | 352 (97.0) | – | |||
| Outcome | Retained (AU + WHO guidelines) | No (AUnotWHO Group) | – | 149 (41.0) | – | – |
| Yes | – | 214 (59.0) | – | – | ||
| Covariate | Demographics | Age (years) | 47.36 (12.42) / | – | 46.55 (12.9) / | – |
| 48 (37–56) | 47 (37–55) | |||||
| Sex | ||||||
| Male | – | 331 (91.2) | – | 133 (88.7) 17 (11.3) | ||
| Female | – | 32 (8.8) | – | |||
| Covariate | Psychosocial (PSY) | Financial instability (Yes) | – | 50 (13.8) | – | 22 (14.8) |
| Complexity domain | Dysfunctional CMA use (Yes) | – | 25 (6.9) | – | 12 (8.1) | |
| Mental illness &/or other problematic substance use (Yes) | – | 101 (27.8) | – | 41 (27.5) | ||
| Social Isolation (Yes) | – | 65 (17.9) | – | 27 (18.1) | ||
| Covariate | Physical health (PH) | Cognitive/neurological impairment (Yes) | – | 24 (6.5) | – | 9 (6.0) |
| Complexity domain | Polypharmacy (Yes) | – | 46 (12.7) | – | 18 (12.1) | |
| HCV &/or Cancer (Yes) | – | 18 (5.0) | – | 6 (4.0) | ||
| Other physical health comorbidity (Yes) | – | 119 (32.8) | – | 49 (32.9) | ||
| Covariate | PH and PSY Complexity Domains | Neither PH nor PSY | – | 154 (42.4) | – | 67 (45.0) |
| PH complexity domain only | – | 70 (19.3) | – | 28 (18.8) | ||
| PSY complexity domain only | – | 65 (17.9) | – | 19 (12.8) | ||
| Both PH and PSY | – | 74 (20.4) | – | 35 (23.5) | ||
Multivariable binary logistic regression results for 1) Age and Sex, 2) Comorbidities (with their interaction) and Age and Sex
| Analyses | Variables | Odds Ratio (OR) of AUnotWHO group membership | 95% CI for OR | p | |
|---|---|---|---|---|---|
| Lower | Upper | ||||
| Model 1 (age and sex) | Age (years) | 0.99 | 0.98 | 1.01 | 0.56 |
| Sex (Male) | REF | ||||
| Sex (Female) | 1.70 | 0.79 | 3.66 | 0.17 | |
| Model 2 (comorbidity with age and sex) | Age (years) | 0.99 | 0.97 | 1.01 | 0.23 |
| Sex (Male) | REF | ||||
| Sex (Female) | 1.77 | 0.84 | 3.74 | 0.13 | |
| PH = 0, PSY = 0 | REF | ||||
| PH = 1, PSY = 0 | 0.98 | 0.54 | 1.78 | 0.93 | |
| PH = 0, PSY = 1 | 0.51 | 0.27 | 0.96 | 0.04 | |
| PH = 1, PSY = 1 | 1.22 | 0.68 | 2.19 | 0.50 | |
Exact Wald tests with Firth Bias correction for exploratory interaction analyses
| Interaction | Test statistic (χ2) | |
|---|---|---|
| Financial instability*Problematic CMA use | 2.36 | 0.12 |
| Financial Instability* Mental illness &/or other problematic substance use | 1.17 | 0.28 |
| Financial Instability*Isolation | 0.58 | 0.45 |
| Financial Instability*Cognitive/neurological impairment | 0.54 | 0.46 |
| Financial Instability*Polypharmacy | 0.22 | 0.64 |
| Financial Instability*HCV &/or Cancer | 0.03 | 0.86 |
| Financial Instability*Other physical health comorbidity | 0.06 | 0.81 |
| Problematic CMA use* Mental illness &/or other problematic substance use | 1.00 | 0.32 |
| Problematic CMA use*Isolation | 6.39 | 0.01 |
| Problematic CMA use*Cognitive/neurological impairment | 0.20 | 0.66 |
| Problematic CMA use*Polypharmacy | < 0.01 | 1.00 |
| Problematic CMA use*HCV &/or Cancer | < 0.01 | 0.95 |
| Problematic CMA use*Other physical health comorbidity | 0.01 | 0.92 |
| Mental illness &/or other problematic substance use*Isolation | 0.59 | 0.44 |
| Mental illness &/or other problematic substance use*Cognitive/neurological impairment | 0.05 | 0.82 |
| Mental illness &/or other problematic substance use*Polypharmacy | 0.09 | 0.76 |
| Mental illness &/or other problematic substance use*HCV &/or Cancer | 1.59 | 0.21 |
| Mental illness &/or other problematic substance use*Other physical health comorbidity | 0.22 | 0.64 |
| Isolation*Cognitive/neurological impairment | 0.42 | 0.52 |
| Isolation*Polypharmacy | 0.19 | 0.66 |
| Isolation*HCV &/or Cancer | 0.48 | 0.49 |
| Isolation*Other physical health comorbidity | 0.81 | 0.37 |
| Cognitive/neurological impairment*Polypharmacy | < 0.01 | 0.98 |
| Cognitive/neurological impairment*HCV &/or Cancer | 0.03 | 0.86 |
| Cognitive/neurological impairment*Other physical health comorbidity | 0.49 | 0.48 |
| Polypharmacy*HCV &/or Cancer | 0.31 | 0.58 |
| Polypharmacy*Other physical health comorbidity | 2.34 | 0.13 |
| HCV &/or Cancer*Other physical health comorbidity | 2.70 | 0.10 |
Fig. 2A syndemic model of the synergistic effect of combined PH and PSY complexity domains on retention in care, as outlined in [22]